reported that breast cancer patients with high expression of ATXN3 is correlated with poor prognosis, and downregulation of ATXN3 could increase the sensitivity of breast cancer cells to chemotherapeutic agents (Adriamycin) (45). Here, ATXN3 is linked to breast carcinoma.